Wiesweg M, Herold T, Metzenmacher M, et al. - Experts reported the case of an individual with metastatic lung adenocarcinoma harboring an E3 ubiquitin-protein ligase CBL (c-Cbl) binding site changes and showed a clinical, radiological and metabolic response to crizotinib with a PFS of 10.6 months. As an escape mechanism, a typical MET resistance mutation could be recognized. It was discovered that MET c-Cbl binding site mutations should be acknowledged as a distinct subtype of MET exon 14 alterations. Moreover, patients with lung cancer harboring such mutations should be given targeted therapy.